Masks of polycystic ovary syndrome: the role of inositols
DOI: 10.32364/2618-8430-2024-7-3-8
Masks of polycystic ovary syndrome: the role of inositols
N.V. Dub, E.V. Kruchinina
LLC "Dr. Alexeeva Clinic", Korolev, Russian Federation
Aim: to evaluate the effect of the complex of myo-inositol and D-chiroinositol (MI/DCI) 40:1 in combination with alpha-lipoic acid (ALA) on endocrine and metabolic parameters, body weight, menstrual cycle duration, and pregnancy rate in women with polycystic ovary syndrome (PCOS).
Patients and Methods: 50 women aged 18–35 years who were planning to become pregnant were studied. Group 1 included 30 women who received MI/DCI 40:1 and ALA, folic acid, vitamin D3, and manganese (Diferton supplement) 1 tablet twice daily for 180 days. Group 2 (controls) included 20 women who also received the preconception nutrient complex (docosahexaenoic acid, vitamin D3, folic acid, vitamin E, potassium iodide) for 180 days. All women signed a voluntary informed consent prior to enrollment. Hormonal status, fasting glucose, HOMA-IR, insulin, lipid profile, body weight, body mass index (BMI), waist circumference, menstrual cycle duration at baseline, after 90 and 180 days, and pregnancy rate in both groups were evaluated.
Results: in group 1, Diferton contributed to a significant decrease in total cholesterol and low-density lipoprotein levels and an increase in high-density lipoprotein levels. In group 2, changes in these parameters were also observed, but they were not significant. A decrease in fasting plasma glucose was also observed in group 1 (p<0.01), indicating a significant effect of the studied dietary supplement on carbohydrate metabolism. Women in group 1 lost 3±1.19 kg of body weight in 6 months and waist circumference decreased by an average of 3.1±1.5 cm. Meanwhile, women in group 2 did not lose weight and waist circumference changed insignificantly. In group 1, the menstrual cycle duration decreased to 40±1.9 days, while in group 2, the cycle duration decreased by an average of 4 days. Pregnancy occurred in 6 women in group 1 and in 1 woman in group 2.
Conclusion: Diferton improved not only hormonal and metabolic parameters but also ovarian dysfunction in women with PCOS. It is reasonable to use it for pregravidaral preparation in women with PCOS. Significant decrease in BMI, body weight and waist circumference in group 1 during the treatment is an additional marker of the positive effect of the dietary supplement Diferton on the somatic status of women with metabolic disorders.
Keywords: polycystic ovary syndrome, complex of myo-inositol and D-chiroinositol, alphalipoic acid, metabolic disorders, infertility.
For citation: Dub N.V., Kruchinina E.V. Masks of polycystic ovary syndrome: the role of inositols. Russian Journal of Woman and Child Health. 2024;7(3) (in Russ.) 205–213 (in Russ.). DOI: 10.32364/2618-8430-2024-7-3-8.
ABOUT THE AUTHORS:
Nadezhda V. Dub — C. Sc. (Med.), obstetrician and gynecologist, LLC "Dr. Alexeeva Clinic"; 21, Pushkinskaya str., Korolev, 141090, Russian Federation; ORCID iD 0000-0001-7678-5674.
Elena V. Kruchinina — C. Sc. (Med.), obstetrician and gynecologist, LLC "Dr. Alexeeva Clinic"; 21, Pushkinskaya str., Korolev, 141090, Russian Federation; ORCID iD 0000-0002-3628-0863.
Contact information: Elena V. Kruchinina, е-mail: kruchinina.elena@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 02.06.2024.
Revised 25.06.2024.
Accepted 18.07.2024.
References
1. Goodman N.F., Cobin R.H., Futterweit W. et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome — part 2. Endocr Pract. 2015;21(12):1415–1426. DOI: 10.4158/ P15748.DSCPT2.
2. Meier R.K. Polycystic Ovary Syndrome. Nurs Clin North Am. 2018;53(3):407420. DOI: 10.1016/j.cnur.2018.04.008.
3. Андреева Е.Н., Шереметьева Е.В., Дедов И.И. Синдром поликистозных яичников: этиология, патогенез, диагностика и лечение: научно-практическое руководство. М.: ВИДАР; 2016.Andreeva E.N., Sheremetyeva E.V., Dedov I.I. Polycystic ovary syndrome: etiology, pathogenesis, diagnosis and treatment: scientific and practical guide. Moscow: VIDAR; 2016 (in Russ.).
4. Ali A.T. Polycystic ovary syndrome and metabolic syndrome. Ceska Gynekol. 2015;80(4):279–289. DOI: 10.1093/med/9780190214791.003.0016.
5. Zhao H., Zhang J., Cheng X. et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023;16(1):9. DOI: 10.1186/s13048-022-01091-0.
6. Unfer V., Dinicola S., Russo M. A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes? Int J Mol Sci. 2023;24(7):6213. DOI: 10.3390/ijms24076213.
7. Unfer V., Kandaraki E., Pkhaladze L. et al. When one size does not fit all: Reconsidering PCOS etiology, diagnosis, clinical subgroups, and subgroup-specific treatments. Endocrine Metab Sci. 2024;1114:100159. DOI: 10.1016/j.endmts.2024.100159.
8. Chiaffarino F., Cipriani S., Dalmartello M. et al. Prevalence of polycystic ovary syndrome in European countries and USA: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;279:159–170. DOI: 10.1016/j.ejogrb.2022.10.020.
9. Teede H.J., Tay C.T., Laven J.J.E. et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. DOI: 10.1210/clinem/dgad463.
10. Громова О.А., Стаховская Л,В., Торшин И.Ю. и др. Прием метформина провоцирует нарушение гомеостаза витамина В12. Consilium Medicum. 2017;19(4):58–64. DOI: 10.26442/2075-1753_19.4.58-64.Gromova O.A., Stakhovskaya L.V., Torshin I.Yu. et al. Metformin intake provokes a violation of vitamin B12 homeostasis. Consilium Medicum. 2017;19(4):58–64 (in Russ.). DOI: 10.26442/2075-1753_19.4.58-64.
11. Воронцова А.В., Гаспарян С.А., Громова О.А. и др. Заключение совещания экспертов «Обоснование применения средств на основе инозитола у пациенток с наруше-ниями менструального цикла». Проблемы репродукции. 2020;26(1):44–54. DOI: 10.17116/repro20202601144.Vorontsova A.V., Gasparyan S.A., Gromova O.A. et al. Conclusion of the expert meeting "Justification of the use of inositol-based products in patients with menstrual cycle disorders". Reproduction issues. 2020;26(1):44–54 (in Russ.). DOI: 10.17116/repro20202601144.
12. Ших Е.В., Гребенщикова Л.Ю. Рациональная дотация микронутриентов как способ повышения качества жизни у пациенток с КС. Медицинский совет. 2017;13:104–109.Shikh E.V., Grebenshchikova L.Yu. Rational subsidy of micronutrients as a way to improve the quality of life in patients with CS. Medical Council. 2017;13:104–109 (in Russ.).
13. Gref D. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproduct Biol Endocrinol. 2023;21:10. DOI: 10.1186/s12958-023-01055-z.
14. Пустотина О.А. Инозитолы и липоевая кислота в лечении ИР у женщин с СПЯ. Акушерство и гинекология. 2020;12:199–206.Pustotina O.A. Inositols and lipoic acid in the treatment of IR in women with PCOS. Obstetrics and Gynecology. 2020;12:199–206 (in Russ.).
15. Lind M.V., Lauritzen L., Kristensen M. et al. Effect of folate supplementation on insulin sensitivity and type 2 diabetes: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2019;109(1):29–42. DOI: 10.1093/ajcn/nqy234.
16. Кузнецова И.В., Кононова В.А. Фолиевая кислота и ее роль в женской репродукции. Гинекология. 2014;4:17–23.Kuznetsova I.V., Kononova V.A. Folic acid and its role in female reproduction. Gynecology. 2014;4:17–23 (in Russ.).
17. Тапильская Н.И., Айдуков С.Н. Устранение дефицита фолатов — основная стратегия коррекции гомоцистеинзависимой эндотелиальной дисфункции. Гинекология. 2013;3:70–74.Tapilskaya N.I., Aidukov S.N. Elimination of folate deficiency is the main strategy for correction of homocysteine-dependent endothelial dysfunction. Gynecology. 2013;3:70–74 (in Russ.).
18. He Y., Lu Y., Zhu Q. et al. Influence of metabolic syndrome on female fertility and in vitro fertilization outcomes in PCOS women. Am J Obstet Gynecol. 2019;221(2):138.e1–138.e12. DOI: 10.1016/j.ajog.2019.03.011.
19. He C., Lin Z., Robb S.W., Ezeamama A.E. Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis. Nutrients. 2015;7(6):4555–4577. DOI: 10.3390/nu7064555.
20. Trummer C., Pilz S., Schwetz V. et al. Vitamin D, PCOS and androgens in men: a systematic review. Endocr Connect. 2018;7(3):R95–R113. DOI: 10.1530/EC-18-0009.
21. Krul-Poel Y.H., Koenders P.P., Steegers-Theunissen R.P. et al. Vitamin D and metabolic disturbances in polycystic ovary syndrome (PCOS): A cross-sectional study. PLoS One. 2018;13(12):e0204748. DOI: 10.1371/journal.pone.0204748.
22. Le Donne M., Metro D., Alibrandi A. et al. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2019;23(5):2293–2301. DOI: 10.26355/eurrev_201903_17278.
23. Доброхотова Ю.Э., Лапина И.А., Чирвон Т.Г., Таранов В.В. Новые возможности интегративной терапии пациенток с синдромом поликистозных яичников и наруше-ниями углеводного и липидного обмена. Результаты сравнительного исследования. РМЖ. Мать и дитя. 2020;3(3):169–173. DOI: 10.32364/2618-8430-2020-3-3-169-173.Dobrokhotova Yu.E., Lapina I.A., Chirvon T.G., Taranov V.V. New prospects of the integrative therapy for polycystic ovary syndrome in women with the disorders of carbohydrate and lipid metabolism: a comparative study. Russian Journal of Woman and Child Health. 2020;3(3):169–173 (in Russ.). DOI: 10.32364/2618-8430-2020-3-3-169-173.
24. Bevilacqua A., Dragotto J., Giuliani A., Bizzarri M. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 2019;234(6):9387–9398. DOI: 10.1002/jcp.27623.
25. Чернуха Г.И., Табеева Г.И., Удовиченко М.А. Неиспользованные возможности коррекции эндокринно-метаболических нарушений при синдроме поликистозных яич-ников. Акушерство и гинекология. 2019;10:140–147. DOI: 10.18565/aig.2019.10.140-147.Chernukha G.I., Tabeeva G.I., Udovichenko M.A. Unused Possibilities of Correction of Endocrine-Metabolic Disorders in Polycystic Ovary Syndrome. Obstetrics and Gynecology. 2019;10:140–147 (in Russ.). DOI: 10.18565/aig.2019.10.140-147.
26. Pundir J., Psaroudakis D., Savnur P. et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018;125(3):299–308. DOI: 10.1111/1471-0528.14754.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
